DiagnoCure Inc. reported consolidated financial results for the first quarter ended January 31, 2015. Total revenues for the first quarter of 2015 were $142,915 compared with $146,969 for the same period of 2014. Without taking into account the effect of the exchange rate variation, total revenues decreased by 15%, to $112,381 for the first quarter of 2015 compared with $132,178 for the same period of 2014.

This decrease is mainly attributable to a decrease of 32% in PCA3 European royalty revenues as compared to the same period in 2014. Net loss (before stock-based compensation, depreciation and amortization) was $243,291 against $427,273 a year ago. Basic and diluted net loss per share was $0.01 against $0.01 a year ago.